AbilityPharma Announces € 7 Million Financing Round to Advance Development of its Clinical Phase 2b Autophagy Inducer ABTL0812 in Metastatic Pancreatic Cancer

by Ability Pharma

1 month ago
AbilityPharma, ABTL0812, CTI Life Sciences Fund, Inveready, EIC Fund

AbilityPharma is currently completing an international Phase 2b clinical trial with its product ABTL0812 in patients with metastatic pancreatic cancer, a disease with a very low survival rate, with th...

VHIO is participating prominently in a study that seeks to evaluate the efficacy of a novel combination therapy in advanced pancreatic cancer

by Vall d’Hebron

3 years ago
ABTL0812, Ability Pharmaceuticals, clinical trial, pancreatic cancer

The biopharmaceutical company Ability Pharmaceuticals, SL today announced the inclusion of the first patients in a phase 2b clinical trial with its novel autophagy-inducer anticancer compound ABTL0812...

AbilityPharma capta 3,5 millones de € en una ronda de financiación para finalizar el ensayo fase 2 oncológico actual y licenciar ABTL0812 a una farmacéutica internacional

by Ability Pharma

5 years ago
financiación, ABTL0812, farmacéutica, cáncer, endometrio, pulmón, fármaco

El equipo ejecutivo se refuerza con la incorporación de Maribel Berges como Directora General ascendiendo Carles Domènech a la Presidencia Ejecutiva

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting

by Ability Pharma

5 years ago
clinical trial, oncology drugs, endometrial cancer, lung cancer, ABTL0812

AbilityPharma (Ability Pharmaceuticals, SL) a biopharmaceutical company developing oncology drugs, announced today that the company will release the first results of the currently ongoing phase 1/2...

Ability Pharma announces FDA approval of phase 1/2 trial of ABTL0812 for patients with advanced metastatic pancreatic cancer

by Ability Pharma

6 years ago
ABTL0812, gemcitabine, nab-paclitaxel, metastatic pancreatic cancer

Ability Pharmaceuticals SL, a biopharmaceutical company announced today that the United States Food and Drug Administration (FDA) has approved a phase 1/2 study to assess the efficacy and safety of AB...

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Pancreatic Cancer

by Ability Pharma

7 years ago
ODD, ABTL0812, Pancreatic Cancer, FDA-Orphan Drug Designation

Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug Ad...

Ability Pharmaceuticals Initiates Phase 2 Combination Trial with ABTL0812 as First Line Therapy in Patients with Endometrial or Squamous Lung Cancer Patients

by Ability Pharma

8 years ago
ABTL0812, carboplatin, paclitaxel, cancer, lung, endometrial cancer

ABTL0812 is administered in combination with carboplatin and paclitaxel. Vall d’Hebron Institute of Oncology (VHIO, Barcelona) and Catalan Institute of Oncology (ICO, L’Hospitalet, Barcelona) lead...

Ability Pharmaceuticals enters into a licensing agreement with SciClone Pharmaceuticals for the novel anticancer agent ABTL0812 for the China market

by Ability Pharma

8 years ago
PI3K/Akt/mTOR, ABTL0812, lung cancer, endometrial cancer, SciClone Pharmaceuticals

Collaboration boosts development of a fully differentiated inhibitor of the PI3K/Akt/mTOR pathway. ABTL0812 is currently in Phase 2 clinical trials to treat lung and endometrial cancers.

Ability Pharmaceuticals announces positive Phase 1/1b study results of ABTL0812 in cancer patients with advanced solid tumors

by Ability Pharma

9 years ago
cancer, ABTL0812, drug development, advanced solid tumors

Study confirms that ABTL0812 is extremely well tolerated and shows promising signs of clinical antitumor activity. The results will be presented at AACR-NCI-EORTC International Conference on Molecular...

Ability Pharmaceuticals announces regulatory milestones for ABTL0812 in pediatric cancer neuroblastoma

by Ability Pharma

9 years ago
pediatric cancer, neuroblastoma, orphan-drug, ABTL0812, Food and Drug Administration

Ability Pharmaceuticals today announced that it has received from the U.S. Food and Drug Administration (FDA), orphan-drug designation (ODD) for ABTL0812, its PI3K/Akt/mTOR pathway inhibitor, for the ...